- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19:26 | FDA wants to hear from you on future of advisory committee meetings | ||
| 18:26 | Annovis' shares plummet 60% on another failure for lead Alzheimer's med | ||
| 18:26 | FDA finalizes rule to bring lab-developed tests into the regulatory fold | ||
| 16:26 | FDA approves Abbott's dissolving stent for blocked arteries below the knee | ||
| 15:26 | On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23 | ||
| 15:26 | Janssen-partnered epilepsy drug fails phase 2 trial in latest bad luck for Addex | ||
| 12:26 | Bristol Myers pays $65M to expand Repertoire of autoimmune assets | ||
| Fr | Medtronic snags FDA approval for body-sensing, closed-loop spinal cord stimulator | ||
| Fr | Labcorp picks up Invitae portfolio for $239M in bankruptcy sale | ||
| Fr | Bristol Myers Squibb closes immuno-oncology, cell therapy-focused Redwood City site | ||
| Fr | Gilead gives up on $4.9B antibody as solid tumor plan unravels | ||
| Do | UW's Baker Lab researchers make AI strides in drug-like peptides | ||
| Do | Boston Scientific sees 70% electrophysiology growth after Farapulse pulsed-field ablation launch | ||
| Do | Under new leadership, BioMarin axes 4 candidates and centers on 3 assets | ||
| Do | Regeneron signs Mammoth gene editing deal worth $100M upfront | ||
| Do | Bristol Myers cutting $1.5B in costs in less than 2 years, with 2,200 employees impacted in 2024 | ||
| Do | Destiny calls time on SporeGen COVID collab, while Santhera hands lonodelestat back to Spexis | ||
| Do | AstraZeneca drops GOLDILOX and the porcupine in R&D update | ||
| Do | Sanofi crosses Sjögren's off $5B drug's hit list after phase 2 data disappoint | ||
| Mi | Cidara regains rights to flu med after Janssen makes good on promise to divest | ||
| Mi | To be better at neuroscience, Biogen will invest outside the therapeutic area | ||
| Mi | New AI drug discovery powerhouse Xaira rises with $1B in funding | ||
| Mi | Roche's pipeline rethink hits 20% of new molecules as cancer candidates join discard pile | ||
| Di | Profluent combines LLMs and CRISPR for open-source gene editing project | ||
| Di | Alpine's data room was the most exclusive club in biotech. Then Vertex became the VIP |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
